Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HT-001 for EGFRI-induced Skin Toxicities
NCT05639933Phase 2Recruiting
- Sponsor
- Hoth Therapeutics
- Start
- Jul 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of HT-001 in cutaneous toxicity, acneiform eruption, xerosis cutis and 1 more (5 arms), sponsored by Hoth Therapeutics. Primary endpoints: Acneiform Rash Investigator's Global Assessment Scale at 6 weeks, Area Under the Curve at Day 42 and 1 more. Started Jul 2023; status: recruiting.
02
Drugs
HT-001
03
Conditions
cutaneous toxicityacneiform eruptionxerosis cutisparonychia
Beyond the preview
Go deeper on NCT05639933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05639933.